Search

Your search keyword '"Elias, Sjoerd"' showing total 953 results

Search Constraints

Start Over You searched for: Author "Elias, Sjoerd" Remove constraint Author: "Elias, Sjoerd"
953 results on '"Elias, Sjoerd"'

Search Results

1. Holmium-166 radioembolisation dosimetry in HCC

2. Reclassification of Appendiceal Mucinous Neoplasms and Associated Pseudomyxoma Peritonei According to the Peritoneal Surface Oncology Group International Consensus: Clinicopathological Reflections of a Two-Center Cohort Study

3. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

4. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)

5. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease

6. EGFR-targeted fluorescence molecular imaging for intraoperative margin assessment in oral cancer patients: a phase II trial

9. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

11. Harmonization of Quantitative Parenchymal Enhancement in T1 -Weighted Breast MRI.

12. Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification

13. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma

14. Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging

15. Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity

16. Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness: During or After Chemotherapy

17. Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study

18. The prognostic potential of mammographic growth rate of invasive breast cancer in the Nijmegen breast cancer screening cohort.

19. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.

21. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)

22. Oncologic outcomes of screen-detected and non-screen-detected T1 colorectal cancers

23. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

24. Oncologic outcomes of screen-detected and non-screen-detected T1 colorectal cancers

25. A prediction model for response to immune checkpoint inhibition in advanced melanoma

26. A prediction model for response to immune checkpoint inhibition in advanced melanoma

27. Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer

28. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study

29. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study

30. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease.

31. Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations

32. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease

33. Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer

34. Oncological outcomes of screen-detected and non-screen-detected T1 colorectal cancers

35. A prediction model for response to immune checkpoint inhibition in advanced melanoma

36. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

39. Development and validation of a lifestyle-based model for colorectal cancer risk prediction: the LiFeCRC score

41. Pedunculated Morphology of T1 Colorectal Tumors Associates With Reduced Risk of Adverse Outcome

42. Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer

44. Histologic Factors Associated With Need for Surgery in Patients With Pedunculated T1 Colorectal Carcinomas

45. Triple-Negative and Non–Triple-Negative Invasive Breast Cancer: Association between MR and Fluorine 18 Fluorodeoxyglucose PET Imaging

46. Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention.

47. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

50. Discovery of common and rare genetic risk variants for colorectal cancer

Catalog

Books, media, physical & digital resources